TEVA PHARMACEUTICAL INDUSTRIES LIMITED Operating Lease Right-of-Use Assets
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) had Operating Lease Right-of-Use Assets of $333.00 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-07-29
- 2026-06-30: Operating Lease, Right-of-Use Asset $333.00M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $335.00M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $345.00M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $342.00M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $333.00M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $335.00M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $345.00M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $342.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $358.00M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $363.00M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $367.00M 10-K · filed 2026-02-03 |
| 2024-09-30 | $364.00M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $358.00M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $364.00M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $397.00M 10-K · filed 2025-02-05 |
| 2023-09-30 | $406.00M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $418.00M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $420.00M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $419.00M 10-K · filed 2024-02-12 |
| 2022-09-30 | $422.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $441.00M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $464.00M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $495.00M 10-K · filed 2023-02-10 |
| 2021-09-30 | $507.00M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $531.00M 10-Q · filed 2021-07-28 |
| 2021-03-31 | $529.00M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $559.00M 10-K · filed 2022-02-09 |
| 2020-09-30 | $557.00M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $489.00M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $489.00M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $514.00M 10-K · filed 2021-02-10 |
| 2019-09-30 | $468.00M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $500.00M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $517.00M 10-Q · filed 2019-05-02 |